Docoh
Loading...

MOR Morphosys

News

From Benzinga Pro
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
6 Dec 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector recorded weekly losses, reversing course from the previous week's advance.
12 Health Care Stocks Moving In Monday's Pre-Market Session
22 Nov 21
Pre-Market Outlook, Markets, Movers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 Nov 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For November 10, 2021
10 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial
5 Nov 21
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
21 Oct 21
Biotech, Earnings, News, Penny Stocks, Health Care, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
7 Oct 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
1 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14)
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep 21
Biotech, M&A, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)

Press releases

From Benzinga Pro
Corporate Calendar 2022
29 Nov 21
Press Releases
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follows:Publication of Interim Statement / ReportConference
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
11 Nov 21
Earnings, Press Releases
Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-QTen abstracts, including two oral presentations, accepted at upcoming ASHPelabresib data for arm 3 of MANIFEST study to be
MorphoSys Announces Departure of Roland Wandeler
9 Nov 21
News, Press Releases
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and
MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting
4 Nov 21
News, Press Releases
Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4, 2021 / MorphoSys
MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
4 Nov 21
News, Press Releases
- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data- MANIFEST
MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021
2 Nov 21
News, Press Releases
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to € 18.6 million
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
20 Oct 21
News, Press Releases
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
11 Oct 21
Press Releases
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food and Drug